Q4 2024 Esperion Therapeutics Inc Earnings Call Transcript
Key Points
- Esperion Therapeutics Inc (ESPR) received US FDA approval for expanded labels for NEXLETOL and NEXLIZET, making them the only FDA-approved non-statins to lower LDL-cholesterol and reduce the risk of myocardial infarction and coronary revascularization.
- The company achieved 12% sequential quarterly growth in total retail prescription equivalents (TRPEs) in Q4 2024, with expanded payer access covering over 173 million lives in the US.
- Esperion Therapeutics Inc (ESPR) has entered into international partnerships, including with CSL Seqirus in Australia and New Zealand, and Neopharm Israel, which are expected to drive future revenue growth.
- The company reported a 114% increase in total revenue for Q4 2024 compared to the same period in 2023, with significant growth in both US net product revenue and collaboration revenue.
- Esperion Therapeutics Inc (ESPR) has a strong financial position with cash and cash equivalents of $144.8 million as of December 31, 2024, and expects to finish 2025 with an even stronger cash position.
- The company faces risks and uncertainties associated with forward-looking statements, as highlighted under the Safe Harbor provision.
- Esperion Therapeutics Inc (ESPR) experienced an exceptional impact from the Medicare coverage gap in Q4 2024, affecting revenue alignment with TRPE growth.
- Research and development expenses decreased by 38% in Q4 2024 compared to the same period in 2023, primarily due to the completion of the CLEAR Outcomes study, indicating potential challenges in sustaining R&D momentum.
- Selling, general, and administrative expenses decreased by 19% in Q4 2024 compared to the same period in 2023, primarily due to onetime legal expenses, which may not be sustainable in the long term.
- Esperion Therapeutics Inc (ESPR) is still in the process of evaluating potential in-licensing or acquisition opportunities, which may delay portfolio expansion and pipeline advancement.
Ladies and gentlemen, thank you for standing by and welcome. (Operator Instructions) Please be advised that today's conference call may be recorded. I would now like to turn the call over to Alina Venezia, Director of Investor Relations for Esperion Therapeutics. You may begin.
Thank you, operator. Good morning, and welcome to Esperion's fourth-quarter and full-year 2024 earnings conference call. With us on today's call are Sheldon Koenig, President and CEO; and Ben Halladay, CFO. Other members of the executive team will be available for Q&A following our prepared remarks.
We issued a press release earlier this morning detailing the content of today's call. A copy can be found on the Investor page of our website together with a copy of the presentation that we will also be referencing.
I want to remind callers that information discussed on the call today is covered under the Safe Harbor provision of the Private Securities Litigation Reform Act. I caution listeners that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
